Skip to content

CorMedix CRMD Available for sale investments

Available for sale investments at other companies

Merck & Co. logo
Merck & Co.MRK
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
Baxter International logo
Baxter InternationalBAX
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's available for sale investments?
CorMedix (CRMD) reported available for sale investments of $8.5M in Q4 2025.
How has CorMedix's available for sale investments changed year-over-year?
CorMedix's available for sale investments decreased by 75.1% year-over-year, from $34.16M to $8.5M.
What is the long-term trend for CorMedix's available for sale investments?
Over 3 years (2022 to 2025), CorMedix's available for sale investments has grown at a -28.2% compound annual growth rate (CAGR), from $22.96M to $8.5M.